Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2477
Real-time Quote. Real-time Tradegate - 10/24 04:01:45 pm
85.128 EUR   +0.27%
8h ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -..
8h agoDJFlu-Shot Supply Dented by Production Woes
9h agoDJFlu-Shot Supply Dented by Production Woes
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Latest news on SANOFI
8h ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -sourc..
8h agoDJFlu-Shot Supply Dented by Production Woes
9h agoDJFlu-Shot Supply Dented by Production Woes
9h ago GENZYME : BioMarin Announces Third Quarter 2014 Financial Results
17h agoDJSanofi SA 3Q 2014-- Forecast
17h ago SANOFI : Information concerning the total number of voting rights and shares
1d ago GENZYME : iTraumaCare Positions New Leader for Next-Level Growth
1d agoSANOFI SA : quaterly earnings release
1d ago SANOFI : Restates Commitment to Wellness in Nigeria
1d ago GENZYME : Reports Results from Two Phase III Studies
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF